Want to see COCH full AI Analyst Report?

Envoy Medical (COCH) Price & Analysis

125 Followers

COCH Stock Chart & Stats

$0.69

-$0.05(-3.47%)

At close: Jan 08 4:00 PM EST

$0.69

-$0.05(-3.47%)

Day’s Range― - ―

52-Week Range$0.36 - $1.89

Previous CloseN/A

Volume61.49K

Average Volume (3M)394.38K

Market Cap

$57.81M

Enterprise Value-$10.75M

Total Cash (Recent Filing)$25.25M

Total Debt (Recent Filing)$889.00K

Price to Earnings (P/E)―

Beta0.24

Next Earnings

Aug 17, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.02

Shares Outstanding76,881,110

10 Day Avg. Volume193,663

30 Day Avg. Volume394,378

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-1.10

Price to Sales (P/S)53.77

P/FCF Ratio-0.70

Enterprise Value/Market Cap-0.19

Enterprise Value/Revenue-45.94

Enterprise Value/Gross Profit14.79

Enterprise Value/Ebitda0.50

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.95

Revenue Forecast (FY)$200.00K

Bulls Say, Bears Say

Bulls Say

Differentiated Fully‑implanted ProductEnvoy’s Acclaim and Esteem technologies are fully implanted systems designed to deliver continuous hearing without external processors. This product differentiation can produce durable clinical and usability advantages versus external devices, aiding surgeon adoption, patient compliance, and long‑term market positioning if regulatory/commercial execution succeeds.

Low Leverage; Improved Equity BaseThe company’s low reported leverage and positive equity position reduce immediate solvency pressures and provide more runway flexibility than highly indebted peers. This structural improvement supports continued R&D and commercialization activities without near‑term debt refinancing risk, assuming cash burn is managed.

Improving Free Cash Flow TrendWhile FCF remains negative, management notes an improving FCF trend year over year. A durable trajectory of declining cash burn would extend runway and reduce financing frequency, improving chances to reach commercial inflection points and limiting long‑term dilution if sustained through commercialization execution.

Bears Say

High Ongoing Cash BurnPersistent ~-$20M annual operating cash outflow indicates the business consumes significant capital to fund development and operations. Over months this necessitates external financing, which can dilute shareholders or impose restrictive covenants, and constrains resources available for manufacturing scale-up, reimbursement efforts, and surgeon training important for durable commercialization.

Minimal Revenue, Negative Unit EconomicsRevenue remains extremely small relative to operating costs and gross profit is negative, indicating current unit economics do not support scaling. Without measurable improvement in sales mix, pricing, or cost structure over months, the company faces structural hurdles to reach sustainable margins and fund growth from operations alone.

Nasdaq Listing Compliance RiskA continued bid‑price deficiency and reliance on Nasdaq extensions create structural listing risk. Potential remedies like reverse splits or aggressive market support can impair investor confidence, complicate equity incentives and future financings, and represent a recurring corporate governance and capital‑structure headwind over the next several months.

Envoy Medical News

Envoy Medical Ends ATM Equity Program Amid Capital Confidence

Envoy Medical ( ($COCH) ) has provided an update. Envoy Medical, Inc., a Nasdaq-listed hearing health company, develops...

3d ago

COCH

Envoy Medical signs multi-part series with New to The Street

Envoy Medical (COCH) has signed a multi-part national media series with New to The Street. The campaign is...

1M ago

COCH

Envoy Medical Granted Extension to Regain Nasdaq Compliance

Envoy Medical ( ($COCH) ) just unveiled an announcement. Envoy Medical, Inc. disclosed that on November 19, 2025,...

1M ago

COCH

Envoy Medical Shareholders Expand Equity and Governance Plans

Envoy Medical ( ($COCH) ) has provided an announcement. At its May 12, 2026 annual meeting, Envoy Medical...

2M ago

COCH

COCH Upcoming Earnings Report: What to Expect?

Envoy Medical, Inc. Class A (COCH) is scheduled to report 1st quarter earnings on 05/20/2026, before the market...

2M ago

COCH

Envoy Medical Flags Limited Risk Detail, Urges Investors to Review 2026 Form 10-K for Key Uncertainties

Envoy Medical, Inc. Class A (COCH) has disclosed a new risk, in the Regulation category. Envoy Medical, Inc....

2M ago

COCH

Envoy Medical initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Envoy Medical (COCH) with a Buy rating and $2.50 price target Envoy is...

3M ago

COCH

Envoy Medical Regains Nasdaq Listing Compliance After Financing

Envoy Medical ( ($COCH) ) has issued an update. On February 24, 2026, Envoy Medical announced it had...

4M ago

COCH

Envoy Medical Closes Upsized Public Offering to Fund Growth

Envoy Medical ( ($COCH) ) just unveiled an announcement. On February 12, 2026, Envoy Medical announced the closing...

5M ago

COCH

Envoy Medical Grants Stock Options to Key Executives

Envoy Medical ( ($COCH) ) has provided an update. On February 5, 2026, Envoy Medical, Inc.’s compensation committee...

5M ago

COCH

Envoy Medical Extends Shortfall Warrants, Enhancing Capital Flexibility

The latest announcement is out from Envoy Medical ( ($COCH) ). On December 18, 2025, Envoy Medical, Inc....

6M ago

COCH

Envoy Medical files to sell Class A common stock, no amount given

17:22 EST Envoy Medical (COCH) files to sell Class A common stock, no amount given Published first on...

7M ago

COCH

Envoy Medical Updates Investors on Strategic Plans

Envoy Medical ( ($COCH) ) has shared an update. Envoy Medical has released an updated investor presentation detailing...

7M ago

COCH

Envoy Medical announces four new patents

Envoy Medical (COCH) announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US...

2y ago

COCH

COCH FAQ

What was Envoy Medical’s price range in the past 12 months?

Envoy Medical lowest stock price was $0.36 and its highest was $1.89 in the past 12 months.

What is Envoy Medical’s market cap?

Envoy Medical’s market cap is $57.81M.

When is Envoy Medical’s upcoming earnings report date?

Envoy Medical’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.

How were Envoy Medical’s earnings last quarter?

Envoy Medical released its earnings results on May 11, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.06.

Is Envoy Medical overvalued?

According to Wall Street analysts Envoy Medical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Envoy Medical pay dividends?

Envoy Medical does not currently pay dividends.

What is Envoy Medical’s EPS estimate?

Envoy Medical’s EPS estimate is -0.08.

How many shares outstanding does Envoy Medical have?

Envoy Medical has 76,881,110 shares outstanding.

What happened to Envoy Medical’s price movement after its last earnings report?

Envoy Medical reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -0.155%.

Which hedge fund is a major shareholder of Envoy Medical?

Currently, no hedge funds are holding shares in COCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Envoy Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

239.44%

Trailing 12-Months

Asset Growth

187.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Envoy Medical

Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.